Company: PFSA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001013762-25-004396
Chunk: 1142

Company: Profusa, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7A
Chunk 1142
---
 warrant. Such units would be identical
to the private placement warrants, including as to exercise price, exercisability and exercise period.

●Our
initial stockholders, officers and directors may be owed reimbursement for expenses incurred in connection with certain activities on
our behalf which would only be repaid if we complete an initial business combination.

●Our
officers and directors may be paid consulting, finder or success fees for assisting us in consummating our initial business combination.

55

The conflicts described above
may not be resolved in our favor.

In general, officers and directors
of a corporation incorporated under the laws of the State of Delaware are required to present business opportunities to a corporation
if:

●the
corporation could financially undertake the opportunity;

●the
opportunity is within the corporation’s line of business; and

●it
would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation.

We are not prohibited from
pursuing an initial business combination with a company that is affiliated with our initial stockholders, officers or directors. In the
event we seek to complete our initial business combination with such a company, we, or a committee of independent directors, would obtain
an opinion from an independent investment banking firm which is a member of FINRA, or from an independent accounting firm, that such an
initial business combination is fair to our company from a financial point of view.

In the event that we submit
our initial business combination to our public stockholders for a vote, our sponsor, executive officers, and directors have agreed to
vote their founder shares and any public shares purchased in or after our initial public offering in favor of our initial business combination.

The following table summarizes
the relevant pre-existing fiduciary or contractual obligations of our officers and directors:

    Individual 
    Entity 
    Position at affiliated entity
  
    Jack Stover 
    Onconova Therapeutics, Inc. 
    Director

    Fred Knechtel 
    - 
    -

    Peter O’Rourke 
    TCI Partners 
    Managing Partner

    AXIM Biotechnologies 
    Director

    Ed Johnson 
    iONEBIOSUSA 
    CEO

    Johnson Global Ventures LLC 
    CEO

    Advantage Capital Partners 
    Advisor

    Lauren Chung 
    MINLEIGH, LLC 
    CEO

    Todos Medical Ltd. 
    Director

Limitation on Liability and Indemnification
of Officers and Directors

Our